Case Reports in Oncological Medicine最新文献_第7页

A Novel Approach for Stereotactic Radiosurgery of Multiple Brain Metastasis in a Patient With Poor Performance Status: A Case Report. 一种新的立体定向放射手术治疗多发性脑转移患者的表现不佳：1例报告。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-12-22 eCollection Date: 2025-01-01 DOI: 10.1155/crom/3420915

Arad Iranmehr, Shakiba Sheikholeslami, Nooshin Banaee, Mohammad Shirani, Mostafa Farzin, Fatemeh Jafari

{"title":"A Novel Approach for Stereotactic Radiosurgery of Multiple Brain Metastasis in a Patient With Poor Performance Status: A Case Report.","authors":"Arad Iranmehr, Shakiba Sheikholeslami, Nooshin Banaee, Mohammad Shirani, Mostafa Farzin, Fatemeh Jafari","doi":"10.1155/crom/3420915","DOIUrl":"10.1155/crom/3420915","url":null,"abstract":"Background: Brain metastases are the most common malignant intracranial tumors in adults. The management of patients with poor performance status and multiple brain metastases remains controversial, with guidelines generally recommending palliative care in such cases. Stereotactic radiosurgery has been debated for this group of patients, particularly those with multiple lesions.Case presentation: We present a case of an Iranian patient with metastatic non-small cell lung cancer (NSCLC) who had previously undergone whole-brain irradiation (WBRT). The patient was referred due to the progression of multiple brain lesions. In response, we administered two separate courses of fractionated stereotactic radiation therapy (FSRT) to treat these brain masses. The patient's neurological symptoms showed significant improvement following the treatment.Conclusions: This case suggests that stereotactic radiation therapy can be considered for patients with poor performance status, regardless of the number of brain metastases. It may stabilize or improve neurological deficits and enhance the patient's quality of life, even if its effect on overall survival is uncertain. Additionally, treating the lesions in two separate courses may reduce treatment time and facilitate better repair of normal brain tissue.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"3420915"},"PeriodicalIF":0.6,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Aggressive Case of Thymic Lymphoepithelial Carcinoma Complicated by Cytokine Release Syndrome: A Case Report. 侵袭性胸腺淋巴上皮癌合并细胞因子释放综合征1例。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-12-17 eCollection Date: 2025-01-01 DOI: 10.1155/crom/4842642

Louis G Filipiak, Nyembezi L Dhliwayo, Koosha Paydary

引用次数: 0

Chemotherapy-Induced Cardiotoxicity With Frontline BV-AVD for Hodgkin Lymphoma. 化疗诱导的一线BV-AVD治疗霍奇金淋巴瘤的心脏毒性

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-12-16 eCollection Date: 2025-01-01 DOI: 10.1155/crom/4690413

Angelo Rizzolo, Caroline Michel, Nathalie A Johnson

引用次数: 0

Long-Term Survival With Olaparib Maintenance Therapy in Metastatic Pancreatic Carcinoma of a Patient Harboring Germline BRIP1 and ATM Mutations. 奥拉帕尼维持治疗转移性胰腺癌患者的长期生存携带种系BRIP1和ATM突变。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-12-16 eCollection Date: 2025-01-01 DOI: 10.1155/crom/9962240

Ruemu E Birhiray, Maya N Birhiray, Samuel L Ranger, Vincent L Flanders

{"title":"Long-Term Survival With Olaparib Maintenance Therapy in Metastatic Pancreatic Carcinoma of a Patient Harboring Germline BRIP1 and ATM Mutations.","authors":"Ruemu E Birhiray, Maya N Birhiray, Samuel L Ranger, Vincent L Flanders","doi":"10.1155/crom/9962240","DOIUrl":"10.1155/crom/9962240","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the United States, causing approximately 50,000 deaths annually. Among PDAC patients, those with germline BRCA1/2 mutations show a more favorable response to platinum-based chemotherapy and PARP inhibitors like olaparib. The 2019 randomized placebo-controlled double-blind Phase 3 POLO trial demonstrated olaparib's efficacy as a first-line maintenance therapy in patients with BRCA-mutated metastatic PDAC following platinum-based chemotherapy. Olaparib was subsequently approved by the FDA, EMA, and PMDA. However, this treatment approach has not been extended to other homologous recombination deficiency (HRD)-related mutations. This case report details a 72-year-old white, female patient with cogermline mutations in the ATM and BRIP1 genes, both of which are involved in DNA repair pathways, resulting in HRD. Following a diagnosis of metastatic PDAC, the patient achieved complete remission after retreatment with FOLFIRINOX and has maintained remission for over 40 months on olaparib maintenance therapy. Her ongoing remission, coupled with undetectable levels of circulating tumor DNA, supports olaparib's potential effectiveness in HRD-positive PDAC beyond BRCA mutations. This case highlights the need for expanded HRD testing and consideration of PARP inhibitor maintenance therapy for PDAC patients with HRD pathway deficiencies. Our findings advocate for further clinical studies to assess the broader applicability of PARP inhibitors in PDAC patients with HRD mutations, including ATM and BRIP1, which could enhance survival outcomes in this high-risk population. Expanding the standard of care to include PARP inhibitors for HRD-positive PDAC could address a critical gap in treatment and improve patient prognosis.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"9962240"},"PeriodicalIF":0.6,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Definitive Chemoradiation for Unresectable Hyalinizing Clear Cell Carcinoma of the Base of the Tongue: A Molecularly Confirmed Case. 不能切除的舌底透明透明细胞癌的最终放化疗：1例分子证实病例。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-12-15 eCollection Date: 2025-01-01 DOI: 10.1155/crom/6717205

Paul J Pecorin, Mary Allen-Proctor, Samer Al-Khudari, Daniel W Golden, Koosha Paydary

{"title":"Definitive Chemoradiation for Unresectable Hyalinizing Clear Cell Carcinoma of the Base of the Tongue: A Molecularly Confirmed Case.","authors":"Paul J Pecorin, Mary Allen-Proctor, Samer Al-Khudari, Daniel W Golden, Koosha Paydary","doi":"10.1155/crom/6717205","DOIUrl":"10.1155/crom/6717205","url":null,"abstract":"Hyalinizing clear cell carcinoma (HCCC) is a rare malignancy of the minor salivary glands, most often managed by surgical resection. We report a case of a 63-year-old woman with an unresectable base-of-tongue tumor initially presumed to be squamous cell carcinoma. Histopathologic evaluation and molecular testing ultimately confirmed HCCC with an EWSR1-ATF1 fusion. Given the tumor's extent, she was treated with definitive chemoradiation using weekly cisplatin and 70 Gy in 35 fractions. Her course was complicated by pulmonary embolism, neutropenia, and severe mucositis requiring percutaneous endoscopic gastrostomy tube placement. Post-treatment imaging showed decreased FDG avidity, and circulating tumor DNA remained negative for minimal residual disease. This case highlights the importance of molecular diagnostics in distinguishing HCCC from other clear cell neoplasms and suggests a potential role for chemoradiation in unresectable cases, though treatment-related toxicity remains a significant concern. Further investigation into systemic and targeted therapies for HCCC is warranted.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"6717205"},"PeriodicalIF":0.6,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypertriglyceridemia-Induced Acute Pancreatitis Associated with Ruxolitinib for Hemophagocytic Lymphohistiocytosis: A Case Report. 高甘油三酯血症引起的急性胰腺炎与鲁索利替尼治疗噬血细胞淋巴组织细胞增多症：1例报告。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-12-10 eCollection Date: 2025-01-01 DOI: 10.1155/crom/7271334

Sarah Medina, Leslie A Ynalvez, Hyeon-Ju Ryoo Ali, Maria E Cabanillas, Ihab Hamzeh, Salil Kumar, Nicolas Palaskas, Anita Deswal, Shaden Khalaf

{"title":"Hypertriglyceridemia-Induced Acute Pancreatitis Associated with Ruxolitinib for Hemophagocytic Lymphohistiocytosis: A Case Report.","authors":"Sarah Medina, Leslie A Ynalvez, Hyeon-Ju Ryoo Ali, Maria E Cabanillas, Ihab Hamzeh, Salil Kumar, Nicolas Palaskas, Anita Deswal, Shaden Khalaf","doi":"10.1155/crom/7271334","DOIUrl":"10.1155/crom/7271334","url":null,"abstract":"Ruxolitinib is a Janus kinase inhibitor that has been associated with lipid abnormalities, including a 15% incidence of hypertriglyceridemia. We describe a case of a 37-year-old man with refractory T-cell lymphoma treated with ruxolitinib for hemophagocytic lymphohistiocytosis (HLH). Following ruxolitinib use, the patient developed severe epigastric abdominal pain with elevated amylase, lipase, and triglycerides. This led to a suspicion of hypertriglyceridemia-induced pancreatitis requiring an insulin infusion. Unfortunately, the patient experienced multiorgan failure and expired. While ruxolitinib has been associated with hypertriglyceridemia, severe lipid abnormalities, as observed in this case, are rare. Furthermore, assessing the incidence of severe hypertriglyceridemia in the setting of HLH is challenging, given that the disease itself contributes to elevated triglyceride levels. This case highlights the need for a more vigilant approach in monitoring lipid parameters when using ruxolitinib for HLH treatment, especially among patients with concomitant risk factors.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"7271334"},"PeriodicalIF":0.6,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myocarditis Mimicking Takotsubo Cardiomyopathy With First Dose of Neoadjuvant Nivolumab-Relatlimab. 心肌炎模拟Takotsubo心肌病与第一剂新辅助nivolumab - relatlimumab。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-12-10 eCollection Date: 2025-01-01 DOI: 10.1155/crom/1443004

Rohit Rao, Felicia Tejawinata, Tejasi Sachdeva, Imran Rashid, Michael Zacharias, Jessica Siegel, McKay Herpel, Akihiro Yoshida, Luke D Rothermel, Iris Y Sheng, Ankit Mangla

{"title":"Myocarditis Mimicking Takotsubo Cardiomyopathy With First Dose of Neoadjuvant Nivolumab-Relatlimab.","authors":"Rohit Rao, Felicia Tejawinata, Tejasi Sachdeva, Imran Rashid, Michael Zacharias, Jessica Siegel, McKay Herpel, Akihiro Yoshida, Luke D Rothermel, Iris Y Sheng, Ankit Mangla","doi":"10.1155/crom/1443004","DOIUrl":"10.1155/crom/1443004","url":null,"abstract":"Neoadjuvant use of immune checkpoint inhibitors (ICIs) is the new standard of care in patients with clinical stage III melanoma. However, it is associated with immune-related adverse events (irAEs). Nivolumab-relatlimab in the neoadjuvant setting is an NCCN-recommended treatment for patients with clinical stage III melanoma. Anti-LAG3 molecule comes with an increased risk of cardiac irAE, especially myocarditis. Takotsubo cardiomyopathy (TTC), a reversible decline in heart function driven by catecholamine overload, is reported as a cardiac irAE in the literature. However, the mechanism of TTC being an irAE is elusive. It is known that myocarditis and TTC share a lot of common features, although the presence of cardiac inflammation essentially rules out TTC. Here, we report the case of an elderly patient with a history of heart failure with midrange ejection fraction, diagnosed with clinical stage III melanoma, who developed shortness of breath with the first dose of neoadjuvant nivolumab-relatlimab. Cardiac magnetic resonance (CMR) imaging demonstrated a severe apical hypokinesis and no myocardial edema, suggestive of TTC. However, since myocarditis could not be ruled out, the patient was started on high-dose methylprednisolone followed by a 9-week taper of prednisone. The CMR changes reverted to baseline 44 days later, with the patient experiencing complete recovery. He underwent wide local excision of the primary melanoma and complete lymph node dissection, which showed a major pathologic response. Postoperatively, he remains on surveillance with no evidence of recurrence. This report emphasizes early recognition of cardiac irAEs and initiation of corticosteroids, which could help prevent morbid long-term complications.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"1443004"},"PeriodicalIF":0.6,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Rare Case of Akathisia After Removal of Subdural Hematoma During Treatment for Malignant Pleural Mesothelioma: Akathisia Induced by Brain Injury or Immune Checkpoint Inhibition. 恶性胸膜间皮瘤治疗中硬膜下血肿切除后出现静坐症一例：脑损伤或免疫检查点抑制所致静坐症。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-12-05 eCollection Date: 2025-01-01 DOI: 10.1155/crom/8854694

Tomomi Wada, Yukihiro Yano, Emi Miyamoto

{"title":"A Rare Case of Akathisia After Removal of Subdural Hematoma During Treatment for Malignant Pleural Mesothelioma: Akathisia Induced by Brain Injury or Immune Checkpoint Inhibition.","authors":"Tomomi Wada, Yukihiro Yano, Emi Miyamoto","doi":"10.1155/crom/8854694","DOIUrl":"10.1155/crom/8854694","url":null,"abstract":"Akathisia is a movement disorder primarily caused by antipsychotic medications. Although extremely rare, cases caused by immune checkpoint inhibitors or traumatic brain injury have also been reported. We report on the case of an 82-year-old patient with malignant pleural mesothelioma who developed akathisia following subdural hematoma removal and achieved successful symptom control. Three months after receiving nivolumab and ipilimumab, the patient developed incomplete paralysis of the right side of the body. Examination and medical history revealed that a subdural hematoma was the cause of the movement abnormality. Following hematoma removal, the patient became unable to sit still. We suspected the condition as akathisia secondary to traumatic brain injury. Anticholinergic medication successfully controlled the symptoms, allowing treatment for mesothelioma to resume. Neurological immune-related adverse events associated with immune checkpoint inhibitors are often difficult to resolve completely and can lead to discontinuation of cancer treatment. We hope this case report underscores the importance of carefully evaluating the pathophysiology of neurological abnormalities arising during cancer treatment.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"8854694"},"PeriodicalIF":0.6,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relapsed Classical Hodgkin Lymphoma in Pregnancy in Two Patients Managed With a Multidisciplinary Approach. 两例妊娠期复发经典霍奇金淋巴瘤患者多学科联合治疗。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-12-01 eCollection Date: 2025-01-01 DOI: 10.1155/crom/3286507

Minhal Zaidi, Amna Naqvi, Jacqueline Rios, Meera Khosla, Hala Hassanain, Noah Giese, Ethan A Burns, Hanh Mai, Carrie Yuen, Shilpan Shah, Siddhartha Ganguly, Sai Ravi Pingali

{"title":"Relapsed Classical Hodgkin Lymphoma in Pregnancy in Two Patients Managed With a Multidisciplinary Approach.","authors":"Minhal Zaidi, Amna Naqvi, Jacqueline Rios, Meera Khosla, Hala Hassanain, Noah Giese, Ethan A Burns, Hanh Mai, Carrie Yuen, Shilpan Shah, Siddhartha Ganguly, Sai Ravi Pingali","doi":"10.1155/crom/3286507","DOIUrl":"10.1155/crom/3286507","url":null,"abstract":"Relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL) during pregnancy is rare, and management is often complex. The following two cases of r/r cHL during pregnancy highlight management considerations and outcomes in this unique patient population. The first patient with Stage IIIB cHL achieved a complete response (CR) with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) prior to pregnancy but relapsed at 10 weeks of gestation. She was maintained with methylprednisolone and vinblastine with no complications until she underwent cesarean section at 34 weeks. The second patient, diagnosed with Stage IIIb cHL, achieved CR after five cycles of ABVD and one cycle of AVD. She began consolidation radiation but halted treatment after two cycles upon discovering an intrauterine twin pregnancy. At 10 weeks of gestation, she experienced a relapse of her disease. The patient received one cycle of vinblastine and methylprednisolone weekly. At 31 weeks, the patient underwent an elective cesarean section. After delivery, both patients underwent ICE (ifosfamide, carboplatin, and etoposide), followed by consolidation with autologous hematopoietic cell transplantation (auto-HCT). These cases highlight the balance needed to maintain control of disease to allow a safe and uneventful pregnancy.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"3286507"},"PeriodicalIF":0.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12685414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Successful Rechallenge in a Patient With Oxaliplatin-Induced Tonic-Clonic Seizures Under Anticonvulsant Therapy. 在抗惊厥药物治疗下奥沙利铂诱导的强直-阵挛性癫痫患者的成功再挑战。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-11-30 eCollection Date: 2025-01-01 DOI: 10.1155/crom/4707066

Mona Mirzaee, Behrad Azadmehr, Saeid Haji Aghajani, Zahra Jahangard-Rafsanjani

{"title":"A Successful Rechallenge in a Patient With Oxaliplatin-Induced Tonic-Clonic Seizures Under Anticonvulsant Therapy.","authors":"Mona Mirzaee, Behrad Azadmehr, Saeid Haji Aghajani, Zahra Jahangard-Rafsanjani","doi":"10.1155/crom/4707066","DOIUrl":"10.1155/crom/4707066","url":null,"abstract":"Background: Oxaliplatin is an alkylating chemotherapeutic agent which is FDA-approved for colorectal cancer treatment. The most frequent neurologic complication reported with oxaliplatin is acute peripheral neuropathy. Posterior reversible encephalopathy syndrome (PRES) is another neurologic adverse effect that has been reported with oxaliplatin-based chemotherapy regimens resulting in seizures. Oxaliplatin-induced seizure in the absence of PRES is rare and has been reported in four case reports.Case presentation: We report a case of tonic-clonic seizures after oxaliplatin administration in the absence of any other abnormal radiological or laboratory findings in a 58-year-old male diagnosed with rectal adenocarcinoma. In this case, tonic-clonic seizures occurred a few hours after oxaliplatin administration in two episodes lasting 1 min each, two and a half hours apart. The patient's vital signs, EEG, and brain MRI showed no abnormalities. The patient received levetiracetam after the seizure onset and was successfully retreated with oxaliplatin 6 months later.Conclusion: This case highlights a rare presentation of oxaliplatin-induced seizure occurring in the absence of PRES or other identifiable metabolic, structural, or infectious causes. Notably, successful rechallenge with oxaliplatin was achieved after a prolonged seizure-free interval and under antiepileptic coverage, suggesting that rechallenging may be considered in selected patients following multidisciplinary evaluation.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"4707066"},"PeriodicalIF":0.6,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0